Core Viewpoint - A class action securities lawsuit has been filed against Coupang, Inc. for alleged securities fraud affecting investors between August 6, 2025, and December 16, 2025 [1] Group 1: Allegations of the Lawsuit - The complaint alleges that Coupang had inadequate cybersecurity protocols, allowing a former employee to access sensitive customer information for nearly six months without detection [2] - It is claimed that this breach subjected Coupang to increased regulatory and legal scrutiny [2] - The lawsuit states that when the defendants became aware of the data breach, they failed to report it in compliance with SEC reporting rules, rendering their public statements materially false and misleading [2] Group 2: Investor Participation - Investors who suffered losses during the specified timeframe have until February 17, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving RxSight, Inc. and its executives [1] Group 1: Management Changes - RxSight announced the departure of its Chief Financial Officer, Shelley Thunen, who will remain until her successor is appointed or by January 31, 2026 [2] - The departure of Thunen was noted as surprising by financial services firm BTIG, especially given early signs of operational improvement and a recent management reshuffle [2] - The timing of these leadership transitions suggests ongoing commercial challenges for RxSight, potentially delaying a broader recovery into 2026 despite some recent progress [2] Group 2: Stock Performance - Following the announcement of Thunen's departure, RxSight's stock price fell by $1.22 per share, representing a decline of 9.98%, closing at $11.01 per share on December 23, 2025 [3]

Core Viewpoint - Kirby McInerney LLP is investigating potential claims against Soleno Therapeutics, Inc. regarding possible violations of federal securities laws or unlawful business practices [1] Group 1: Company Overview - Soleno Therapeutics, Inc. is under scrutiny following a report by Scorpion Capital that criticized its only product, Vykat XR, labeling it as overpriced and potentially unsafe for children [2] - The company's stock price experienced significant declines following negative reports and disclosures about Vykat XR, with a drop of approximately 7.41% on August 15, 2025, and a further decline of about 26.59% on November 5, 2025 [2][3] Group 2: Financial Impact - Following the Scorpion Capital report, Soleno's share price fell from $77.36 to $71.64, a decrease of $5.73 per share [2] - On November 4, 2025, Soleno disclosed a discontinuation rate of approximately 8% for Vykat XR due to adverse effects, which contributed to a further decline in share price from $63.85 to $46.87, a drop of $16.98 per share [3]

Core Viewpoint - Mereo BioPharma Group plc is under investigation for potential securities fraud and unlawful business practices following disappointing Phase 3 study results for its treatment setrusumab, which led to a significant drop in stock price [1][3][4]. Group 1: Company Performance - Mereo announced results from two Phase 3 studies for setrusumab, a treatment aimed at conditions affecting bone metabolism [3]. - Neither study met the primary endpoints of reducing the annualized clinical fracture rate compared to placebo or bisphosphonates, although both achieved secondary endpoints related to improvements in bone mineral density with strong statistical significance [3]. - Following the announcement, Mereo's stock price plummeted by $2.02 per share, a decrease of 87.64%, closing at $0.28 per share on December 29, 2025 [4]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Mereo investors regarding possible securities fraud or other unlawful business practices by the company and its officers and/or directors [1].

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of California, captioned Kim v. Synopsys, Inc., et al., No. 3:25-cv-09410 [3]. - Investors have until December 30, 2025, to request to be appointed to lead the case [3]. Group 2: Company Performance - Synopsys provides design automation software products, with its Design IP segment being the fastest-growing, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. - The company reported a revenue of $425.9 million for its Design IP segment in Q3 2025, reflecting a 7.7% decline year-over-year, and a net income of $242.5 million, a 43% year-over-year decline [6]. Group 3: Market Reaction - Following the release of disappointing Q3 2025 results, Synopsys stock fell from $604.37 per share to $387.78 per share, a decline of nearly 36% [6]. - The company indicated that its Design IP customers were requiring more customization, which was affecting the economics of its business model [5].

Core Viewpoint - The article discusses the administrative penalties imposed by the China Securities Regulatory Commission (CSRC) on Hongda Xingye Co., Ltd. and its underwriter, First Capital Securities Co., Ltd., due to violations related to the issuance of convertible bonds in 2019, including misappropriation of funds and false disclosures [1][3][10]. Group 1: Administrative Penalties - First Capital Securities' subsidiary, First Capital Securities Underwriting and Sponsorship Co., Ltd., failed to perform due diligence during the ongoing supervision of Hongda Xingye's 2019 convertible bond project, leading to false records in supervisory documents [1][8][9]. - The CSRC's Jiangsu Regulatory Bureau ordered corrections, issued warnings, confiscated underwriting business income, and imposed fines on First Capital Securities and its representatives [1][9]. Group 2: Violations by Hongda Xingye - Hongda Xingye allegedly changed the use of raised funds without authorization, involving an amount of 1,691,280,000 yuan, with 69,000,000 yuan in 2019 and 1,622,280,000 yuan in 2020, primarily used by its controlling shareholder and related parties [3][10]. - The company’s annual reports from 2019 to 2022 and the semi-annual report for 2023 contained false records regarding the use of raised funds and financial performance, including inflated revenues and profits [3][10]. Group 3: Legal Actions and Investor Compensation - Due to the violations, affected investors are encouraged to register for compensation claims through legal representation, with specific conditions for eligibility based on their investment timeline [5][12]. - The compensation claims are based on the legal framework that holds companies and their executives accountable for damages caused by false statements, including investment losses and related costs [4][11].

Core Viewpoint - Changyuan Technology Group Co., Ltd. (referred to as Changyuan Group or ST Changyuan) is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, leading to a formal case being opened against the company [1][5]. Group 1: Company Announcement - On December 27, 2025, Changyuan Group announced that it received a notice from the CSRC regarding the initiation of an investigation due to alleged violations of information disclosure laws [1][5]. - Previously, on April 29, 2025, the company issued a correction notice regarding prior accounting errors and related periodic report corrections [6]. Group 2: Legal Implications for Investors - Investors who purchased Changyuan Group's stocks or bonds between July 1, 2023, and April 28, 2025, and sold or continued to hold them after April 29, 2025, may register for compensation claims [2][6]. - The compensation scope includes investment differences, commissions, and stamp duties, as per the Civil Code and Securities Law [6]. Group 3: Legal Process and Requirements - Investors seeking compensation must provide specific documentation, including a copy of their ID, a securities account confirmation, and transaction records [7]. - The progress of civil claims may be affected by the company's potential delisting or bankruptcy proceedings [3][7].

Core Viewpoint - Changjiang Pharmaceutical Holdings Co., Ltd. (*ST Changyao) is facing administrative penalties from the China Securities Regulatory Commission (CSRC) for financial misconduct, including false reporting of revenue and profits over multiple years [2][6]. Group 1: Financial Misconduct - The company acquired 52.75% of Hubei Changjiang Xing Pharmaceutical Co., Ltd. in November 2020, which was subsequently consolidated into its financial statements [2][6]. - From 2021 to 2023, the subsidiaries of Changjiang Xing fabricated inventory and sales documents, leading to inflated revenues of CNY 215.32 million, CNY 283.74 million, and CNY 233.63 million, representing 9.12%, 17.57%, and 19.51% of reported revenues respectively [2][6]. - The inflated total profits during the same period were CNY 56.40 million, CNY 63.38 million, and CNY 43.71 million, accounting for 35.62%, 88.23%, and 6.42% of the reported total profits [2][6]. Group 2: Potential Consequences - The company may face mandatory delisting due to continuous false reporting of financial indicators over three years, as per the Shenzhen Stock Exchange rules [3][7]. - On November 7, 2025, the company announced it was under investigation for suspected false reporting of financial data [8]. Group 3: Investor Compensation - A law firm is collecting claims from investors who purchased shares between April 28, 2022, and November 6, 2025, and either sold or held the shares after November 7, 2025 [4][8]. - Investors may seek civil compensation for losses incurred due to the company's fraudulent activities, which could include differences in investment, commissions, and stamp duties [8].

Core Viewpoint - A class action securities lawsuit has been filed against Stride, Inc. for alleged securities fraud affecting investors between October 22, 2024, and October 28, 2025 [1] Group 1: Allegations Against Stride - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students" [2] - It is alleged that Stride cut staffing costs by assigning teachers caseloads beyond statutory limits [2] - The company is accused of ignoring compliance requirements, including background checks and licensure laws for employees, as well as federally mandated special education services [2] - Whistleblowers who documented financial directives from Stride's leadership were reportedly suppressed to preserve profit margins [2] - The company allegedly lost existing and potential enrollments due to these practices [2] Group 2: Legal Process and Participation - Investors who suffered losses during the relevant time frame have until January 12, 2026, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the U.S. [4]

Core Viewpoint - A class action securities lawsuit has been filed against Coupang, Inc. alleging securities fraud related to inadequate cybersecurity protocols and failure to report a data breach [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between August 6, 2025, and December 16, 2025 [1]. - The complaint claims that Coupang had inadequate cybersecurity measures that allowed a former employee to access sensitive customer information for nearly six months without detection [2]. - It is alleged that the company did not report the data breach in compliance with SEC reporting rules, leading to materially false and misleading public statements [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until February 17, 2026, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].